• LLY-507 and SMYD2: What the Evidence Shows

  2026-10-14

  A 2023 preclinical study linked pharmacological SMYD2 inhibition with reduced cisplatin-associated renal injury, fibrosis, and inflammatory signaling in mice, while also exposing important limits in causal attribution and material provenance. The findings support SMYD2 as a research-relevant regulator in this model, but they do not establish clinical efficacy, broad CKD applicability, or the performance of a particular commercial formulation.

• MK-571: Interpreting the Evidence Gaps

  2026-10-14

  MK-571, also known as L-660,711, is described as a cysteinyl leukotriene receptor 1 antagonist, but the supplied evidence does not establish a direct comparison with alternative leukotriene-pathway tools. Interpretation is further limited by reported activity at the ABCC1/MRP1 transporter and by the species and model differences across preclinical studies.

• Dacomitinib and METTL17: Evidence Boundaries

  2026-10-13

  The supplied study identifies METTL17 as a mitochondrial regulator associated with ferroptosis resistance and tumor progression in colorectal cancer models. Dacomitinib is a separate pan-ErbB research compound; the available evidence does not establish that it affects METTL17, mitochondrial translation, or ferroptosis in colorectal cancer.

• Drying mRNA-LNPs: Promise and Limits

  2026-10-13

  Zhen et al. review how freeze-drying and related drying technologies may address the storage challenges of mRNA and other nucleic-acid lipid nanoparticles. The article presents drying as a stability strategy rather than a demonstrated universal replacement for frozen storage, emphasizing that outcomes depend on nucleic-acid structure, nanoparticle properties and the evidence available for each platform.

• Nuclear cGAS and LINE-1 Genome Defense

  2026-10-12

  A 2023 Nature Communications study links nuclear cGAS to suppression of LINE-1 retrotransposition through a CHK2–TRIM41 pathway that promotes ORF2p degradation. The findings expand cGAS biology beyond cytosolic DNA sensing, but they do not establish that BML-277 was used or that pharmacological Chk2 inhibition would reproduce the reported effects.

• Hydrocortisone and Splicing-Metastasis Evidence Gaps

  2026-10-12

  The supplied Oncogene study supports a DAPK3–TIA1–CLSTN1 mechanism in breast-cancer models, but its use of hydrocortisone as a culture-medium component does not compare hydrocortisone conditions or establish glucocorticoid effects. The evidence is therefore contextual rather than pharmacological.

• PI Nanoliposomes and Cellular Immunity

  2026-10-11

  The cited Journal of Controlled Release study presents a preclinical nanovaccine concept intended to strengthen CD8 T-cell responses by combining phosphatidylinositol-associated immune activation with proposed endoplasmic-reticulum-directed antigen delivery. Its reported results are promising in murine ovalbumin tumor models, but the supplied evidence does not establish clinical efficacy, safety, or applicability to human cancers.

• CCR5-Positive Extracellular Vesicles in Rheumatoid Arthritis

  2026-10-10

  A 2025 study links CCR5-bearing extracellular vesicles from rheumatoid arthritis synovial fibroblasts with cartilage destruction, bone erosion, and NF-κB activation in cellular and rat models. Its key innovation is to treat CCR5 as an extracellular-vesicle-associated mediator of joint pathology and to compare CCR5-deficient vesicles with vesicle-associated Maraviroc, while recognizing that the evidence remains preclinical.

• L-Phenylephrine and Sex-Aware Adrenergic Research

  2026-10-09

  L-Phenylephrine is described as an adrenergic α1A receptor agonist, but its receptor binding profile should not be equated with organism-level causality. In conscious mice, chronic angiotensin II produced a larger blood-pressure increase in males than females, while the supplied study used phenylephrine as a baroreflex probe rather than as a direct test of the C3021 product.

• From CYP2C19 Probes to Human Intestinal Organoids

  2026-10-09

  A translational perspective on using (S)-Mephenytoin as a CYP2C19 substrate within human pluripotent stem cell-derived intestinal models, with emphasis on evidence boundaries, validation strategy, and pharmacokinetic relevance.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-10-08

  A 2025 study established a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be differentiated into intestinal epithelial cells with enterocyte-associated cytochrome P450 and transporter activities, supporting a more human-relevant platform for pharmacokinetic studies while leaving important questions about maturation, reproducibility, and quantitative predictive performance open.

• Catalpol and Cardio-Cerebrovascular Protection

  2026-10-08

  The 2023 review by Zhang and colleagues synthesizes preclinical evidence that Catalpol may protect against atherosclerosis, myocardial injury, cardiac remodeling, and related vascular disorders through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. Its main contribution is an integrated map of disease phenotypes, signaling pathways, pharmacokinetic considerations, and evidence gaps, while emphasizing that clinical evidence remains limited.

• Luminescent ATP Assay in NSCLC Ferroptosis Research

  2026-10-07

  A source-grounded overview of ATP measurement in a 2026 NSCLC ferroptosis study, including the conceptual role of firefly luciferase assays, evidence strength, product-reported capabilities, and important limitations.

• How p38α Inhibitors Control Dephosphorylation

  2026-10-06

  A 2024 bioRxiv preprint reports that selected p38α MAP kinase inhibitors can do more than block catalytic activity: they can also accelerate WIP1-mediated dephosphorylation by stabilizing a phosphatase-accessible activation-loop conformation. The work introduces a conformation-directed framework for kinase inhibition while emphasizing that the findings remain primarily biochemical and structural rather than clinically validated.

• Carbapenemase Transmission in Enterobacter cloacae

  2026-10-06

  Chen et al. integrated gene localization, antimicrobial susceptibility, transfer assessment, mobile-element analysis, and strain typing to examine carbapenem-resistant Enterobacter cloacae across eight Guangdong teaching hospitals. The study identifies plasmid-associated blaNDM-1 and multidrug resistance as major surveillance concerns, while showing that laboratory transfer findings should be interpreted as evidence of dissemination potential rather than direct proof of hospital transmission.

8586 records 1/573 page Next 12345 下5页 Last page